Discussion Topic:Â New-Onset Atrial Fibrillation Prediction: the HARMS2-AF Risk Score
Deepthy Varghese, MSN, ACNP, FNP, of Northside Hospital, is joined by guests Sandeep K. Goyal, MD, FHRS, Piedmont Heart Institute, and Andrea M. Russo, MD, FHRS, Cooper University Hospital. to discuss the article explores that development and validation of the HARMS2-AF score, a novel lifestyle risk assessment tool for identifying atrial fibrillation (AF) risk in the general population. Using data from the UK Biobank and Framingham Heart Study, the score, derived through Cox proportional hazards regression, includes variables like hypertension, age, body mass index, sex, sleep apnea, smoking, and alcohol. Physical inactivity and diabetes were not significant predictors. The score demonstrated effective predictive performance in both cohorts, outperforming existing models like Framingham-AF and ARIC, and comparable to CHARGE-AF. In conclusion, the HARMS2-AF score is a valuable tool for lifestyle-related AF risk identification, aiding in population screening and potential early intervention.
Host:Â Deepthy Varghese, MSN, ACNP, FNP
Guests:Â Sandeep K. Goyal, MD, FHRS and Andrea M. Russo, MD, FHRS
Speaker and Article Information:Â Download
Visual Aid:Â Download
Topic
- The Lead
Resource Type
- Podcasts
Related Resources
The Lead
Podcasts
The Lead Episode 149: Heart Rhythm 2026 Late-Breaker Coverage: A Discussion of Safety and Performance of a Novel ICD Lead for Left Bundle Branch Area Pacing: Results from the ASCEND CSP Trial
May 14, 2026
The Lead
Podcasts
The Lead Episode 150: Heart Rhythm 2026 Late-Breaker Coverage: A Discussion of Total Fatal Adverse Events Following Atrial Fibrillation Ablation Reported in an FDA Mandatory Reporting System: A Matter of Concern? The TiFFANY Study
May 14, 2026
The Lead
Podcasts
The Lead Episode 148: The Lead Episode 148: HRS 2026 Late-Breaker Coverage, A Discussion of Ventricular Intramyocardial Navigation and Tachycardia Ablation Guided by Electrograms (VINTAGE): First-in-Human Experience with a Novel Therapy for Refractory Ventricular Arrhythmias
May 14, 2026